Chi­nese start­up with Mer­ck vet at the helm ac­quires rights to Oys­ter Point's eye dis­ease nasal spray

With the Chi­nese drug mar­ket start­ing to bear fruit, West­ern drug­mak­ers have looked to wig­gle their way in, of­ten lean­ing on lo­cal part­ners to do the grunt work on the ground. With so many Chi­nese com­pa­nies play­ing the will­ing host, a fledg­ling start­up with a Mer­ck vet­er­an lead­ing the way will now take on an­oth­er West­ern part­ner of its own.

Ji Xing Phar­ma­ceu­ti­cals has ac­quired the Greater Chi­nese rights to Oys­ter Point Phar­ma’s nasal spray for dry eye dis­ease can­di­dates OC-01 and OC-02 in ex­change for $17.5 mil­lion in up­front cash and 0.75% eq­ui­ty in the emerg­ing Chi­nese biotech, the part­ners said Thurs­day.

The deal comes with $204.8 mil­lion in biobucks and serves as the sec­ond West­ern part­ner­ship for Ji Xing, an RTW In­vest­ments-backed com­pa­ny head­quar­tered in Shang­hai that emerged from stealth last month with an undis­closed B round in hand.

Joe Ro­manel­li

The firm is helmed by Joe Ro­manel­li, the for­mer pres­i­dent of Mer­ck Chi­na who over­saw the launch of 20 prod­ucts in that re­gion, in­clud­ing I/O su­per­star Keytru­da and HPV vac­cine Gar­dasil, which the biotech said was the biggest drug by rev­enue in Chi­na pro­duced by a multi­na­tion­al.

Dur­ing his four-year tenure with the New Jer­sey drug­mak­er, Ro­manel­li over­saw its evo­lu­tion from the sev­enth-largest multi­na­tion­al drug­mak­er op­er­at­ing in Chi­na to the sec­ond by the time he jumped ship.

“Stim­u­lat­ing nat­ur­al tear film pro­duc­tion may be a par­a­digm-chang­ing way to treat dry eye dis­ease, which af­fects more than 150 mil­lion pa­tients in Chi­na,” Ro­manel­li said about the Oys­ter Point deal. “We are ex­cit­ed to part­ner with the Oys­ter Point team, who are in­no­v­a­tive pi­o­neers fo­cused on de­vel­op­ing ther­a­peu­tics for oph­thalmic dis­eases, and bring both OC-01 and OC-02 to Chi­na.”

Ji Xing’s oth­er West­ern part­ner­ship, a li­cens­ing deal with Mile­stone Phar­ma­ceu­ti­cals, is al­so for a nasal spray, this time for parox­ys­mal supraven­tric­u­lar tachy­car­dia and oth­er car­dio­vas­cu­lar in­di­ca­tions. The drug, dubbed etri­pamil, is cur­rent­ly in Phase III test­ing.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.

Ex­elix­is pulls a sur­prise win in thy­roid can­cer just days ahead of fi­nal Cabome­tyx read­out

Exelixis added a thyroid cancer indication to its super-seller Cabometyx’s label on Friday — months before the FDA was expected to make a decision, and days before the company was set to unveil the final data at #ESMO21.

At a median follow-up of 10.1 months, differentiated thyroid cancer patients treated with Cabometyx (cabozantinib) lived a median of 11 months without their disease worsening, compared to just 1.9 months for patients given a placebo, Exelixis said on Monday.

Volker Wagner (L) and Jeff Legos

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Ten years ago, a small Norwegian biotech by the name of Algeta showed up at ESMO — then the European Multidisciplinary Cancer Conference 2011 — and declared that its Bayer-partnered targeted radionuclide therapy, radium-223 chloride, boosted the overall survival of castration-resistant prostate cancer patients with symptomatic bone metastases.

In a Phase III study dubbed ALSYMPCA, patients who were treated with radium-223 chloride lived a median of 14 months compared to 11.2 months. The FDA would stamp an approval on it based on those data two years later, after Bayer snapped up Algeta and christened the drug Xofigo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.

Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.

Mi­rati tri­umphs again in KRAS-mu­tat­ed lung can­cer with a close­ly watched FDA fil­ing now in the cards

After a busy weekend at #ESMO21, which included a big readout for its KRAS drug adagrasib in colon cancer, Mirati Therapeutics is ready to keep the pressure on competitor Amgen with lung cancer data that will undergird an upcoming filing.

In topline results from a Phase II cohort of its KRYSTAL-1 study, adagrasib posted a response rate of 43% in second-line-or-later patients with metastatic non-small cell lung cancer containing a KRAS-G12C mutation, Mirati said Monday.

Den­mark's Gubra to col­lab­o­rate with Bay­er on pep­tides; Sam­sung and Bio­gen re­ceive FDA ap­proval for Lu­cen­tis biosim­i­lar

Danish biotech Gubra announced a research collaboration and license agreement with Bayer to develop peptide therapeutics to treat cardiorenal diseases. The collaboration will utilize Gubra’s peptide drug discovery platform to identify potential candidates.

This is not the first time Gubra has partnered with a company on peptide therapeutics — they partnered with Boehringer Ingelheim back in 2017 to create peptide therapeutics to treat obesity.